

THE FDA MEDICAL PRODUCTS REPORTING PROGRAM



McNEIL ( FOR, .....

£ FDA on 11/15/60

A. Patient inf	ormatio	<u></u>			-C. Suspect m	-diantian				
1. Patient identifier	2. Ago at ti		3. Bex	4. Weight	C. Suspect m			ותשים		
	of event	8 yrs	( )fomele	unk lbs						
<b>-</b>	Or		` , ,	or	#2					
In confidence	of birth:		(X)male	kgs	2. Dose, frequency &	mids mad	12 Thomas do	(id)		
B. Adverse e	vent or p	product proble		Dose, frequency & route used     3. Therapy dates (if unknown, give duration) from/to (or best estimate)						
1. X Adverse event and/or Product problem (e.g., defects/malfunctions)					#1 "as recommended", po #1 unknown date				s or duration	
<ol><li>Outcomes attribute (check all that app</li></ol>		event			#2		#2			
( ) disability					4. Diagnosis for use (indication)				5. Event abeted after use stopped or dose reduced	
( ) death ( ) congenital anomaly ( ) life-threatening ( ) required intervention to prevent					#1 stomach cramps					
( ) life-threatening ( ) required intervention to prevent permanent impairment/demage				#2			#1 (	) Yes ( ) No (X) N,		
(4)		( ) atha	r.		6. Let # (if known)	17. Eve	data (if known)	4	) Yes ( ) No ( ) N,	
3. Date of event	<del></del>	4. Date of this repe			#1 Unknown	#1	Unknown		t reappeared after	
(mo/dev/hr)	1		02/13/98		#2	-   <sub>82</sub>			roduction	
5. Describe event or	problem	(moldsy/yr)						Jan (	) Yes ( ) No (X) N/	
·					9. NDC # - for product problems only (if known)					
Report of LIVER DAMAGE, ENCEPHALOPATHY and PANCREATITIS in a								#2 (	Yes ( ) No ( ) N/	
		ild abuse. Acc			10. Concernitant medic	el products a	and therapy date	s (exclud	e treatment of eventi	
		had given acet	•		DIMETAPPO					
		recommended"; d taken to the ER								
		stomach cramps								
		matient was tran			G. All manufac	eturore				
					1. Contact office - near		miling site for	devices)	2. Phone number	
hospital for care. MD diagnosed patient w/acetaminophen toxicity (OVERDOSE) based on an acetaminophen level of					McNeil Consumer Products Company				215-233-7820	
77.7 mcg/ml drawn 15 hrs after admission to 2nd hospital.					Nedical Affair					
Pt was transferred to ICU & further diagnosed w/					7050 Camp Hill Road				3. Report source (check all that apply	
pencreatitis, encephalopathy and 30% of liver cells were					Ft. Washington, PA 19034				( ) foreign	
destroyed. Reportedly treatment was mostly unknown to									( ) study	
reporter except that pt was put in a barbiturate comm. On 2/12/98, pt was weaned off barbiturates and removed from									( ) literature	
liver transplant list and continues to improve.									( ) consumer	
			ipi ove.		4. Date resalved by me	nufactures   5			health ( ) professional	
				(ma/day/yr) 02/13/98 (A) NDA # 17-			52	( ) professional		
				6. If IND, protocol #		IND #		, , , , , , , , , , , , , , , , , , , ,		
					• • • • • • • • • • • • • • • • • • • •	i	PLA #		company ( ) representative	
8. Relevent tests/lebe	-	<del>-</del>				- 1	pre-1938 (	) Yes	( ) distributor	
		cetaminophen le		mland	7. Type of report		отс		(x) other:	
the following day acetami		nophen level=2 r	ncg/ml		(check all that apply)	- 1		) Yes	Police	
					( ) 5-day (X)15-d	18.	Adverse event	term(s)	<u> </u>	
					( ) 10-day ( ) periodic (X) Initial ( ) follow-up #		OUTBOOK A LINE COLLEGE			
				(X) Initial ( ) follow-up # OVERDOSE  ENCEPHALOPATH				LIVER DAMAGE  HY PANCREATITIS		
				9. Mfr. report number			101 P/	ANUKEATTIES		
7. Other relevant histo	orv. includia-	Dree vietien medical	conditions to -	allamica	0933572A					
race, pregnancy, s	moking and i	ilcohol use, hepatic/i	renal dysfunction	, etc.)	E. Initial reporte	er				
hx of attention deficit disorder and one prior incident of					1. Name, address & pho					
child abuse										
				i						
				ļ						
			·		2. Health professional?	3. Occupatio	on 4		porter also port to FDA	
		sion of a report de			( ) Yes (X) No	police	investia	-	es ( ) No (Y) tlok	